Case report of a successful treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) bacteremia and MRSA/vancomycin-resistant Enterococcus faecium cholecystitis by daptomycin

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 5, 2011, Pages 2458-2459

  Tascini, Carlo ^a   Di Paolo, Antonello ^b   Polillo, Marialuisa ^b   Ferrari, Mauro ^b   Lambelet, Paola ^c   Danesi, Romano ^b   Menichetti, Francesco ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Versilia Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; TEICOPLANIN;

AGED; ANTIBIOTIC SENSITIVITY; AORTA DISSECTING ANEURYSM; ARTICLE; BILIARY TRACT DRAINAGE; BLOOD CULTURE; CASE REPORT; CHOLECYSTITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG BILE LEVEL; DRUG BLOOD LEVEL; GRANULOCYTE; HUMAN; INTENSIVE CARE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; CHOLECYSTITIS; DAPTOMYCIN; ENTEROCOCCUS FAECIUM; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 79955537449     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01774-10     Document Type: Article

References (10)

1. Benvenuto, M., D. P. Benziger, S. Yankelev, and G. Vigliani. 2006. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50:3245-3249.
2. Bubalo, J. S., M. Y. Munar, G. Cherala, B. Hayes-Lattin, and R. Maziarz. 2009. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob. Agents Chemother. 53:428-434.
3. Menichetti, F. 2005. Current and emerging serious Gram-positive infections. Clin. Microbiol. Infect. 11(Suppl. 3):22-28.
4. Metzger, R., H. Bonatti, and R. Sawyer. 2009. Future trends in the treatment of serious Gram-positive infections. Drugs Today (Barc.) 45:33-45.
5. Mohr, J. F., L. V. Friederich, S. Yankelev, and K. C. Lamp. 2009. Daptomycin for the treatment of enterococcal bacteriemia: results from the Cubicin Outcome Registry and Experience (CORE). Int. J. Antimicrob. Agents 33:543-548.
6. Polillo, M., et al. 2010. A rapid liquid chromatography method to measure linezolid and daptomycin concentrations in human plasma. Ther. Drug Monit. 32:200-205.
7. Riser, M. S., C. M. Bland, C. N. Rudisill, and P. B. Bookstaver. 2010. Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis. Ann. Pharmacother. 44:1832-1835.
8. Safdar, N., D. Andes, and W. A. Craig. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68.
9. Sheridan, K. R., B. A. Potoski, R. K. Shields, and G. J. Nau. 2010. Presence of adequate intravitreal concentrations of daptomycin after systemic intravenous administration in a patient with endogenous endophthalmitis. Pharmacotherapy 30:1247-1251.
10. Traunmüller, F., et al. 2010. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J. Antimicrob. Chemother. 65:1252-1257.